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The silicon supplement “ch-OSA [choline stabilized
‘orthosilicic’ acid] was developed by Dirk Vanden Berghe
for Bio Minerals n.v.” [1-4]. Here, Dirk Vanden Berghe
provides a list of comments/questions on our recent
publication [5] concerning a different form of supplemen-
tal silicon, namely ‘Monomethylsilanetriol’ (MMST; Si
(OH)3CH3).
We entirely disagree with his concerns but before
addressing these directly, we wish to re-emphasise
important background information. Germane to this is
the understanding of the limitations and concerns
over current supplemental forms of silicon, as dictated
by their aqueous chemistry.
From the diet silicon is absorbed as Si(OH)4
(orthosilicic acid) [6-8]. Any effort to concentrate this
form of silicon leads to self-association, polymerisation
and (nano) silica formation. In ch-OSA, for example, a
high dose quaternary ammonium compound stabilises
these very small nanoparticles of silica to prevent their
aggregation [9] as, for example, is discussed by Iler
[10]. However, in the case of silicon dioxide/silicic acid,
no stabilisers are used and aggregation may proceed
with mixed soluble, nano and micron sized silica species
(note, in this case, silicic acid is used as a ‘catch-all’ for
monomeric and varying degrees of polymeric silica). For* Correspondence: ravin.jugdaohsingh@mrc-hnr.cam.ac.uk
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article, unless otherwise stated.all of these supplemental forms, bioavailability is limited
(absorption less than 20% and as low as 1%) [8]. Moreover,
there are currently significant concerns over nanosilica
and more careful evaluation is required for its safe
ingestion [11,12]. We thus reported on the metabolism
and human safety of a soluble silicon form (MMST)
that is very well absorbed (i.e. equivalent to dietary
orthosilicic acid [8,13]).
Direct responses
Overall, our intention was not to provide a full toxico-
logical report of MMST but, rather, and as stated in our
paper [5], to establish if it contributes to the body pool
of silicon in humans and, if so, whether it was safe in
that setting. We stand firmly by our conclusions that, in
both cases, the answers are “yes”: MMST provided a
marked increase in the body pool of Si according to
state-of-art measures and was safe throughout the
study. Nonetheless, we fully agree that for a formal
safety assessment of MMST, or any (silicon) supplement,
human safety data should be accompanied by specific,
preclinical toxicological data and, as Professor Vanden
Berghe notes, be judged in Europe by the EFSA rather
than by individual academics. Our following responses deal
with the points of his main letter in chronological order:
1. We do not agree that EFSA previously gave a
“negative” opinion on the use of MMST as a
supplement. They were unable to reach a conclusion
as insufficient data were provided [14]. TheCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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underpinning the importance of new findings such
as those provided in our manuscript [5].
2. In the introduction of our paper, previous studies,
when taken together, help to provide a rationale for
our study: they add weight to arguments over the
human safety of MMST rather than being
conclusive in their own right. Indeed, this is partly
why we undertook a more direct human safety
study. As stated in the introduction of our paper,
MMST is used widely in continental Europe without
any reported adverse effects.
3. We concur with EFSA guidance that long term
human safety studies are not required for safety
assessment of food supplements. However, as noted
above, at least some appropriate pre-clinical
toxicological data should be provided. In the context
of diet and dietary supplement assessment, the study
of 22 human subjects over 4 weeks provides
significant and relevant added value to toxicological
assessment in rodents. Indeed, again using ch-OSA
as an example of one of the approved European
silicon supplements, we note the EFSA’s actual
comments of Section 3.3 in their report [15]; “The
petitioner states that no complete toxicological
evaluation was carried out for ch-OSA since it
contains choline and a stabilised form of a natural
occurring silicon compound (orthosilicic acid). Instead,
the petitioner provided the results of a large number of
animal and human supplementation studies”.
Notwithstanding that orthosilicic acid should read
nanosilica, it makes the valid and important point
that dietary supplements do not carry the same onus
of toxicological assessment as therapeutics. Data
may, more commonly, be bridged and evidence is
usually drawn from both direct rodent studies and
human supplementation studies. The process is
robust but, equally, recognises the distinction
between a “food” and a “therapeutic”.
4. We do not support Professor Vanden Berghe’s
implication that “plants” (nor primitive organisms such
as diatoms) should now be used as indicator species for
human safety assessment and, rather, support the
current processes in place. In fact two studies that
Professor Vanden Berghe cites (Blunder et al., 2011 &
Arkles et al., 2013) did not investigate MMST.
5. Data sheets and analytical reports confirmed the
purity of the MMST in aqueous solution with only
background potassium and phosphate ions: no other
components were present when assessed against
stringent analytical criteria.
6. Page 2, line 53 to line 57 of our manuscript [5]
explains why pre-menopausal women may be an
important target population for Si supplementation.We agree that similar investigations could be
undertaken in men and older women, but it is highly
unlikely that any potential detrimental effects would
be seen in these populations and not in young
women. Indeed, we previously reported no
difference in the metabolism of MMST or OSA in
these different populations [8,16].
7. We disagree with Professor Vanden Berghe’s
concerns over our study design. Subjects were used
as their own controls against placebo, in a
randomised and blinded fashion: this is a standard,
robust trial design that allows conclusions to be
drawn in comparing the “active” to “placebo” and
both against baseline. Given that only the active
(MMST), and not placebo, differed from baseline
and there were no effects of order (MMST before
placebo or placebo before MMST), then clearly the
diet over the eight weeks played no significant role.
Secondly, previous work, as we have referenced
[8,13], characterised the acute urinary excretion of
MMST: the ten-hour fast of subjects in our just-
published study [5] was well outside of this period.
Indeed, that only 10% of the increase in total urinary
silicon post supplementation could be accounted for
by MMST proves that there was little carry over.
Thirdly, the finding of very low urinary levels of
MMST in a few volunteers at baseline or after
ingesting only placebo indicates some normal
background environmental exposure. Whilst the
source would be of interest, in the context of this
study the levels were tiny (21 ± 7 μg/L MMST versus
8.5 ± 5 mg/L total Si in the same urine samples) and
in no way could therefore contribute to our findings.
Fourthly, there was no wash out period (see
‘Subjects and methods’ section [5]), and the fact that
there was no effect of treatment order on the
analytical results justifies this decision.
8. Professor Vanden Berghe refers to a comment on
our study that was posted on line by Dr C Exley,
who proposes that valid interpretation of our
findings would require GFR measures. For three of
the outcomes of interest in our publication, namely
raised fasting serum Si as a marker of Si stores,
serum Si:MMST ratios and the safety of MMST,
there is little to be added by such a measure.
However, for the fourth outcome, namely Si:MMST
ratio in urine following supplementation, additional
urinary creatinine measures may have a role-at least
to ward off improbable theories of the data being
erroneous due to alterations in renal handling. Our
long experience with dietary silicon metabolism
studies has taught us that inter-individual variation
leads to far greater variance than intra-individual
urinary Si excretion. Thus we controlled for this
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same volunteers emptied their bladders at the same
time of day on three separate occasions. As noted
above we used the robust design of double bind,
placebo-controlled intervention: the baseline and
placebo intervention yielded no difference in urinary
silicon concentrations. As such, for MMST
intervention to increase the urinary silicon
concentration as an artefact, the supplement would
need to cause an unexpected concentration of
dissolved urinary solids. Our prior work on MMST
absorption and excretion in volunteers has not
revealed changes in urinary volume and, as our
overall objective was to seek Si:MMST ratios
following supplementation, arguments around
improvement of GFR would also need to include
disproportionate concentration of one form of
silicon over the other. The increase in fasting
urinary silicon levels mirrored increases in fasting
serum silicon levels and we stand fully by the
interpretation of these findings.
9. It is not possible that tissue uptake of MMST explains
our data. Ingested MMSTcould not increase total
urinary silicon by the amounts shown AND
simultaneously be partitioned into tissue. The point
we made, that appears to have been missed, is as
follows: of the measured increase in urinary silicon,
only 10% exists in the form of MMST (either as the
tail of the acute excretion or a slower secondary
pathway of excretion). Either way, MMST is clearly
being converted to inorganic silicon since no other
organic form was detected by proton NMR. At these
concentrations inorganic silicon only exists as Si(OH)4.
0. Regarding the use of 29Si NMR for speciation,
Professor Vanden Berghe quotes some idealised,
non-aqueous limit of detection (LOD) work. Under
aqueous conditions in biological samples the limit
of quantitation is greatly compromised. An entire
study with pure 29Si-supplement would not only
be extremely expensive and time consuming but
would still provide samples with insufficient 29Si
for quantitation by the world’s most sensitive 29Si
NMR spectrometera. We took a pragmatic and robust
approach to the problem and used differential analysis
(1H-NMR versus ICPOES) to demonstrate, albeit
indirectly, bioconversion. Coupled with the published
direct metabolism data that we reference we firmly
conclude that supplemental MMST undergoes
metabolism (demethylation and hydroxylation) and
forms Si(OH)4 in vivo in humans. Interestingly, the
work of Côté-Beaulieu et al., (2009) and Arkles et al.,
(2013) that Professor Vanden Berghe cites, also
indicate the in vivo bioconversion of methylsilanetriols
to silicic acid.Conclusion
We fully stand by our statements over the safety and meta-
bolism of MMST in the human setting of our study. We
urge that with the spotlight on nanosilica safety, other forms
of supplemental silicon now provide similar direct safety data.
Endnotes
aIn the 1999 paper referred to by Professor Vanden
Berghe (Knight CTG, Kinrade SD. Silicon-29 nuclear
magnetic resonance spectroscopy detection limits. Anal
Chem 1999, 71:265-267), the authors reported optimal
29Si NMR limits of detection (LOD), based on a 2:1
signal-to-noise ratio (S/N) and using the highest-field
commercial spectrometer available for 29Si NMR, for
hexamethyldisiloxane dissolved in chloroform. Using a
normal one-pulse sequence with a 17 h total run time
(6784 90° pulses with a recycle period of 10 s, attenuated
by the addition of Cr(acac)3 relaxation agent), they
achieved a 2 ppm LOD. They managed to reduce the
LOD to 0.3 ppm by using a DEPT-45 pulse sequence
which transfers polarization to 29Si nuclei from coupled
methyl protons and also permits much faster pulse
recycling. This technique, however, is not possible for
orthosilicic acid, owing to rapid exchange of silanol
protons with water. Moreover, the T1 relaxation time
for dilute orthosilicic acid in blood or urine exceeds
30-40 s (Kinrade SD, Marat K, Knight CTG. Longitu-
dinal 29Si nuclear magnetic relaxation in aqueous alkali-
metal silicate solutions revisited. J Phys Chem 1996,
100:18351-18356). Based on the numbers presented above,
the theoretical LOD for orthosilicic acid in a biofluid
would be approximately 7 ppm (612 90° pulses with a
recycle period of 100 s over 17 h). This would be expected
to decrease to 0.4 ppm if the orthosilicic acid was 100%
enriched in 29Si isotope. In practise, however, the best ex-
perimental LOD that the same authors have ever achieved
in blood, for example, is just under 1 ppm (manuscript in
preparation, Kinrade et al). Unfortunately, the above
LODs are not sufficient for semi-quantitative NMR. High
precision (standard deviation <1%) NMR peak integra-
tion requires at least a 250:1 S/N (Holzgrabe U. Quantita-
tive NMR spectroscopy in pharmaceutical applications.
Progr Nucl Magn Reson Spectr 2010, 57:229-240). Even a
minimal level of precision would require at least a 25:1 S/N
or a biofluid concentration of 25 ppm 29Si.
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